Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies.
A phase I study of trimethylcolchicinic acid (TMCA) given orally once daily for 5 days every 3rd week was performed in 19 patients with advanced malignancies. Myelosuppression and mucositis were the major toxicities observed. Serum TMCA levels were monitored and appear to be useful in predicting toxicities. A partial response was seen in one lymphoma patient and stabilization of disease was noted in one patient each with prostatic and ovarian cancer.
Department of Hematology, School of Medicine, University of Southern California, Los Angeles 90057.
E
E
Hu
R
R
Ko
R
R
Koda
P
P
Rosen
S
S
Jeffers
M
M
Scholtz
F
F
Muggia
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D003078:Colchicine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D012074:Remission Induction; D013280:Stomatitis / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced
D000970:Antineoplastic Agents; C003707:trimethylcolchicinic acid methyl ether; D003078:Colchicine